Log In
Print this Print this

lomibuvir (VX-222) (formerly VCH-222)

  Manage Alerts
Collapse Summary General Information
Company Vertex Pharmaceuticals Inc.
DescriptionNon-nucleoside HCV NS5B polymerase inhibitor
Molecular Target HCV NS5B polymerase
Mechanism of ActionHCV non-structural protein 5B inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat HCV genotype 1 infection in treatment-naïve patients; Treat HCV infection
Regulatory Designation
PartnerTrek Therapeutics PBC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today